pharma news today glp-1 obesity drugs today pharma news obesity glp-1 today GLP-1 Agonists Weight Loss Drugs Market Size Report, 2030 “These are serious medicines…” AIIMS

Description

When you sign up, a licensed healthcare provider reviews your health assessment and determines if you're a candidate

triGLP is a non-prescription nutritional product and is not an FDA-approved treatment for obesity, diabetes or any disease

Stay informed

The results also showed that exenatide treatment was likely to prevent fractures in treated T2DM patients compared with placebo or other anti-hyperglycemic drugs (Zhang et al., 2018)

Since most glucose-dependent insulinotropic polypeptide (GIP) receptor: glucagon-like peptide- 1 receptor (GLP- 1) receptor: glucagon receptor triagonists compete in efficacy with bariatric surgery, the success of these agents in preclinical models and clinical trials suggests a bright future for multi-agonists in the treatment of metabolic diseases